financetom
Business
financetom
/
Business
/
Synovus Q3 revenue and adjusted EPS beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Synovus Q3 revenue and adjusted EPS beat estimates
Oct 15, 2025 2:20 PM

Overview

* Synovus Q3 2025 revenue beats analyst expectations, driven by strong non-interest revenue growth

* Adjusted EPS for Q3 2025 beats consensus

Outlook

* Synovus expects momentum to continue in the final quarter of 2025

* Synovus anticipates merger with Pinnacle to close in Q1 2026

* Company plans to issue 2026 pro forma guidance post-merger

Result Drivers

* NET INTEREST MARGIN EXPANSION - Driven by higher loan yields and hedge maturities, partially offset by higher cash balances

* NON-INTEREST REVENUE GROWTH - Driven by wealth revenue and capital markets income, contributing to overall revenue increase

* STRONG CREDIT PERFORMANCE - Improved non-performing asset and net charge-off ratios

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $615.39 $604.67

Revenue mln mln (13

Analysts

)

Q3 Beat $1.46 $1.35

Adjusted (18

EPS Analysts

)

Q3 EPS $1.33

Q3 Beat $203.93 $189.75

Adjusted mln mln (14

Net Analysts

Income )

Q3 Net $474.69

Interest mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for Synovus Financial Corp ( SNV ) is $58.00, about 17.5% above its October 14 closing price of $47.84

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on Nov. 25 and Nov. 26, sold 5,219 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,309,853. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 79,287 shares of the company, with 78,880 shares held directly and 407 controlled indirectly. SEC...
Cricut Insider Sold Shares Worth $413,221, According to a Recent SEC Filing
Cricut Insider Sold Shares Worth $413,221, According to a Recent SEC Filing
Nov 27, 2024
05:31 PM EST, 11/27/2024 (MT Newswires) -- Arora Ashish, 10% Owner, Director, Chief Executive Officer, on Nov. 25 and Nov. 26, sold 78,095 shares in Cricut ( CRCT ) for $413,221. Following the Form 4 filing with the SEC, Ashish has control over a total of 3,957,038 shares of the company, with 3,957,038 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1828962/000182896224000131/xslF345X05/wk-form4_1732746095.xml ...
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Pushkal Garg, CMO & EVP Dev & Med Affairs, on Nov. 25 and Nov. 26, sold 1,682 shares in Alnylam Pharmaceuticals ( ALNY ) for $422,144. Following the Form 4 filing with the SEC, Garg has control over a total of 18,138 shares of the company, with 17,457 shares held directly and 681...
Atlassian Insider Sold Shares Worth $2,080,255, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $2,080,255, According to a Recent SEC Filing
Nov 27, 2024
05:30 PM EST, 11/27/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on Nov. 27, sold 7,948 shares in Atlassian ( TEAM ) for $2,080,255. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 174,856 shares of the company, with 174,856 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024008022/xslF345X05/primarydocument.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved